H.C. Wainwright Upgrades CytomX Therapeutics (CTMX) to Buy, 'EpCAM ADC Data Are Highly Impressive'
Tweet Send to a Friend
H.C. Wainwright analyst Robert Burns upgraded CytomX Therapeutics (NASDAQ: CTMX) from Neutral to Buy with a price target of $5.00.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
